Drreddys Laboratories | RDY - Sales Revenues


Drreddys Laboratories reported INR789.05M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Aurora Cannabis CAD 38.01M 56.18M Mar/2026
Bayer EUR 10.87B 2.54B Jun/2026
Canopy Growth CAD 71.25M 3.29M Mar/2026
Cipla INR 71.19B 5.78B Jun/2026
Corcept Therapeutics USD 256.15M 91.25M Jun/2026
Drreddys Laboratories INR 789.05M 86.48B Mar/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Novartis USD 14.41B 1.3B Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 265.71M 15.91M Jun/2026
Richter Gedeon HUF 220.2B 5.51B Mar/2026
Sun Pharmaceuticals INR 153B 7.14B Jun/2026
Supernus Pharmaceuticals USD 219.1M 11.39M Jun/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026